Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157353 | 1.00 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5326495 | 1.00 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623032 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5821483 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL10958796 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623037 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623366 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1622513 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5185943 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL679503 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035320-A1 | POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035320-A1 | POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES | NUP205, PABPC1, SARNP | MEN1 1222/4885KMT2A 2891/4885DEGS1 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.